Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial

BACKGROUND: The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if (177)Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive prostate cancer (oHSPC) to prolong the progression-free survival (PFS) and postpone the need for androgen dep...

Descripción completa

Detalles Bibliográficos
Autores principales: Privé, Bastiaan M., Janssen, Marcel J. R., van Oort, Inge M., Muselaers, Constantijn H. J., Jonker, Marianne A., van Gemert, Willemijn A., de Groot, Michel, Westdorp, Harm, Mehra, Niven, Verzijlbergen, J. Fred, Scheenen, Tom W. J., Zámecnik, Patrik, Barentsz, Jelle O., Gotthardt, Martin, Noordzij, Walter, Vogel, Wouter V., Bergman, Andries M., van der Poel, Henk G., Vis, André N., Oprea-Lager, Daniela E., Gerritsen, Winald R., Witjes, J. Alfred, Nagarajah, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Update
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566967/
https://www.ncbi.nlm.nih.gov/pubmed/34736509
http://dx.doi.org/10.1186/s13063-021-05733-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566967/
https://www.ncbi.nlm.nih.gov/pubmed/34736509
http://dx.doi.org/10.1186/s13063-021-05733-4

Ejemplares similares